

Edgar Filing: IGI LABORATORIES, INC - Form SC 13G

IGI LABORATORIES, INC  
Form SC 13G  
January 30, 2013

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. \_\_\_\_)\*

IGI Laboratories, Inc.

(Name of Issuer)

Common Stock, \$0.01 par value

(Title of Class of Securities)

449575109

(CUSIP Number)

December 21, 2012

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: IGI LABORATORIES, INC - Form SC 13G

1) NAME OF REPORTING PERSONS

Amzak Capital Management, LLC

2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)

(b)

3) SEC USE ONLY

4) CITIZENSHIP OR PLACE OF ORGANIZATION

Nevada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5) SOLE VOTING POWER - 0 -

6) SHARED VOTING POWER 4,251,076

7) SOLE DISPOSITIVE POWER - 0 -

8) SHARED DISPOSITIVE POWER 4,251,076

9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,251,076

10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES  
CERTAIN SHARES (SEE INSTRUCTIONS)

11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.9% (1)

12) TYPE OF REPORTING PERSON

OO

(1) Based on 43,132,745 shares of Common Stock outstanding as of December 21, 2012, derived from: (a) 40,352,091 shares of Common Stock outstanding as of November 2, 2012, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 14, 2012; (b) 2,352,941 shares of Common Stock issued by the Issuer in a private placement on December 21, 2012; and (c) 427,713 shares of Common Stock issuable upon the exercise of vested warrants held by the Reporting Person.

Edgar Filing: IGI LABORATORIES, INC - Form SC 13G

1) NAME OF REPORTING PERSONS

Michael D. Kazma

2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)

(b)

3) SEC USE ONLY

4) CITIZENSHIP OR PLACE OF ORGANIZATION

Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5) SOLE VOTING POWER 10,000

6) SHARED VOTING POWER 4,251,076

7) SOLE DISPOSITIVE POWER 10,000

8) SHARED DISPOSITIVE POWER 4,251,076

9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,261,076 (1)

10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES  
CERTAIN SHARES (SEE INSTRUCTIONS)

11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.9% (2)

12) TYPE OF REPORTING PERSON

IN

- (1) Includes 4,251,076 shares of Common Stock held by Amzak Capital Management, LLC, of which the Reporting Person is a manager.
- (2) Based on 43,132,745 shares of Common Stock outstanding as of December 21, 2012, derived from: (a) 40,352,091 shares of Common Stock outstanding as of November 2, 2012, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 14, 2012; (b) 2,352,941 shares of Common Stock issued by the Issuer in a private placement on December 21, 2012; and (c) 427,713 shares of Common Stock issuable upon the exercise of vested warrants held by Amzak Capital Management.

Edgar Filing: IGI LABORATORIES, INC - Form SC 13G

1) NAME OF REPORTING PERSONS  
Gerry Kazma

2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)  
(a)  
(b)

3) SEC USE ONLY

4) CITIZENSHIP OR PLACE OF ORGANIZATION  
Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5) SOLE VOTING POWER	- 0 -
6) SHARED VOTING POWER	4,251,076
7) SOLE DISPOSITIVE POWER	- 0 -
8) SHARED DISPOSITIVE POWER	4,251,076

9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
4,251,076 (1)

10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES  
CERTAIN SHARES (SEE INSTRUCTIONS)

11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
9.9% (2)

12) TYPE OF REPORTING PERSON  
IN

- (1) Includes 4,251,076 shares of Common Stock held by Amzak Capital Management, LLC, of which the Reporting Person is a manager.
- (2) Based on 43,132,745 shares of Common Stock outstanding as of December 21, 2012, derived from: (a) 40,352,091 shares of Common Stock outstanding as of November 2, 2012, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 14, 2012; (b) 2,352,941 shares of Common Stock issued by the Issuer in a private placement on December 21, 2012; and (c) 427,713 shares of Common Stock issuable upon the exercise of vested warrants held by Amzak Capital Management.

Edgar Filing: IGI LABORATORIES, INC - Form SC 13G

Item 1(a). Name of Issuer:  
IGI Laboratories, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:  
105 Lincoln Avenue  
Buena, New Jersey 08310

Item 2(a). Name of Person Filing:  
This Schedule 13G is being filed by each of the following persons (each a "Reporting Person" and together, the "Reporting Persons"):

- (i) Amzak Capital Management, LLC ("Amzak");
- (ii) Michael D. Kazma ("MK"); and
- (iii) Gerry Kazma ("GK").

See Exhibit A for the Reporting Persons' agreement for a joint filing of a single statement on their behalf.

Item 2(b). Address of Principal Business Office:  
The address of the principal business office of each Reporting Person is 1 N. Federal Highway, Suite 400, Boca Raton, FL 33432.

Item 2(c). Citizenship:  
Amzak was organized under the laws of the State of Nevada.  
Each of MK and GK is a citizen of Canada.

Item 2(d). Title of Class of Securities:  
Common Stock, par value \$0.01 per share ("Common Stock").

Item 2(e). CUSIP Number:  
449575109

Item 3. If this statement is filed pursuant to section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:  
Not applicable.

Item 4. Ownership:  
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1:

Each of MK and GK is a manager of Amzak and may be deemed to share voting and investment power with respect to the Common Stock held by Amzak. Each Reporting Person disclaims beneficial ownership of any Common Stock owned by any other Reporting Person.

- (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
- (b) Percent of class: See the response(s) to Item 11 on the attached cover page(s).
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
  - (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
  - (iii) Sole power to dispose or to direct the disposition of: See the

Edgar Filing: IGI LABORATORIES, INC - Form SC 13G

- response(s) to Item 7 on the attached cover page(s).  
(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).

Item 5. Ownership of Five Percent or Less of a Class.

If this Statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.  
Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.  
Not applicable.

Item 8. Identification and Classification of Members of the Group.  
Not applicable.

Item 9. Notice of Dissolution of Group.  
Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under section 240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief,  
I certify that the information set forth in this statement is true,  
complete and correct.

January 25, 2013

AMZAK CAPITAL MANAGEMENT, LLC

By: /s/ Michael Kazma  
Michael Kazma  
President

/s/ Michael Kazma  
MICHAEL KAZMA

/s/ Gerry Kazma  
GERRY KAZMA

EXHIBIT A

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k) (1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13G and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the shares of common stock of IGI Laboratories, Inc. The undersigned hereby further agree that this Joint Filing Agreement be included as an exhibit to such statement and any such amendment. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

January 25, 2013

AMZAK CAPITAL MANAGEMENT, LLC

By: /s/ Michael Kazma  
Michael Kazma  
President

/s/ Michael Kazma  
MICHAEL KAZMA

/s/ Gerry Kazma  
GERRY KAZMA

CUSIP No. 449575109  
SCHEDULE 13G